Top-Rated StocksTop-RatedNASDAQ:MRUS Merus (MRUS) Stock Forecast, Price & News $24.34 -0.47 (-1.89%) (As of 11:08 AM ET) Add Compare Share Share Today's Range$24.32▼$25.0850-Day Range$20.13▼$27.2952-Week Range$12.03▼$27.70Volume18,647 shsAverage Volume319,381 shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$44.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Merus MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside78.7% Upside$44.33 Price TargetShort InterestBearish8.60% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.12) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector625th out of 965 stocksPharmaceutical Preparations Industry291st out of 452 stocks 4.5 Analyst's Opinion Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.33, Merus has a forecasted upside of 78.7% from its current price of $24.81.Amount of Analyst CoverageMerus has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.60% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 16.8, which indicates bearish sentiment.Change versus previous monthShort interest in Merus has recently increased by 5.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRUS. Previous Next 1.2 News and Social Media Coverage News SentimentMerus has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Merus this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for MRUS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Merus is held by insiders.Percentage Held by Institutions90.68% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Merus are expected to grow in the coming year, from ($3.12) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -6.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 4.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Merus (NASDAQ:MRUS) StockMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Read More MRUS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRUS Stock News HeadlinesSeptember 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Biogen (BIIB)September 17, 2023 | americanbankingnews.comMerus (NASDAQ:MRUS) Given Buy Rating at Needham & Company LLCSeptember 22, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 14, 2023 | markets.businessinsider.com10 Analysts Have This to Say About MerusSeptember 8, 2023 | finance.yahoo.comMerus NV (MRUS): A Deep Dive into Its Overvalued StatusAugust 30, 2023 | msn.comMerus: Petosemtamab And Zeno The Driving Forces Behind Investment ReturnsAugust 22, 2023 | benzinga.comMerus Stock (NASDAQ:MRUS), Analyst Ratings, Price Targets, PredictionsAugust 21, 2023 | msn.comTD Cowen Initiates Coverage of Merus N.V (MRUS) with Outperform RecommendationSeptember 22, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 21, 2023 | finance.yahoo.comWill Merus (NASDAQ:MRUS) Spend Its Cash Wisely?August 9, 2023 | msn.comMerus plans for stock offering, size not disclosedAugust 9, 2023 | msn.comStifel Maintains Merus N.V (MRUS) Buy RecommendationAugust 8, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Merus (MRUS)July 28, 2023 | finance.yahoo.comMerus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023July 24, 2023 | benzinga.comExpert Ratings for MerusJuly 18, 2023 | msn.comEF Hutton Reiterates Merus N.V (MRUS) Buy RecommendationJuly 5, 2023 | finance.yahoo.comZenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug AdministrationJuly 1, 2023 | msn.comNeedham Reiterates Merus N.V (MRUS) Buy RecommendationJune 30, 2023 | markets.businessinsider.comAnalyst Expectations for Merus's FutureJune 29, 2023 | msn.comMerus stock jumps 10% after FDA’s action on cancer drugJune 29, 2023 | finance.yahoo.comZenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancerJune 28, 2023 | finance.yahoo.comInstitutional investors may overlook Merus N.V.'s (NASDAQ:MRUS) recent US$113m market cap drop as long-term gains remain positiveJune 17, 2023 | seekingalpha.comMerus: Far More Constructive After Q1, Just Too Pricey At 28x SalesJune 15, 2023 | finanznachrichten.deMerus N.V.: Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial OfficerJune 15, 2023 | msn.comMerus appoints CFOJune 15, 2023 | finance.yahoo.comMerus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial OfficerMay 31, 2023 | finance.yahoo.comMerus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023See More Headlines Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address MRUS Company Calendar Last Earnings8/07/2023Today9/22/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRUS CUSIPN/A CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Forecast$44.33 High Stock Price Forecast$49.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+78.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131,190,000.00 Net Margins-432.68% Pretax Margin-428.44% Return on Equity-69.89% Return on Assets-47.76% Debt Debt-to-Equity RatioN/A Current Ratio4.30 Quick Ratio4.30 Sales & Book Value Annual Sales$41.59 million Price / Sales29.74 Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book4.65Miscellaneous Outstanding Shares49,860,000Free Float47,715,000Market Cap$1.24 billion OptionableNot Optionable Beta0.84 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Sven Ante Lundberg M.D. (Age 60)CEO, Pres & Exec. Director Comp: $953.06kMr. Gregory D. Perry (Age 63)CFO & Principal Financial Officer Comp: $63.76kMr. Peter B. Silverman J.D. (Age 45)EVP, Company Sec., COO, Gen. Counsel, Chief Intellectual Property Officer & Head of US Legal Comp: $601.19kDr. Hui Liu Ph.D. (Age 56)Chief Bus. Officer, Exec. VP & Head of Merus U.S. Comp: $597.7kDr. Andrew Joe M.D. (Age 57)Chief Medical Officer & Sr. VP Comp: $692.74kDr. Hennie HoogenboomCo-Founder and Scientific AdvisorHarry ShumanChief Accounting OfficerMr. Cornelis Adriaan de Kruif Ph.D. (Age 58)CTO & Exec. VP Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Sr. VPMs. Jillian ConnellVP of Investor Relations & Corp. CommunicationsMore ExecutivesKey CompetitorsANI PharmaceuticalsNASDAQ:ANIPBiohavenNYSE:BHVNKiniksa PharmaceuticalsNASDAQ:KNSA89bioNASDAQ:ETNBAurinia PharmaceuticalsNASDAQ:AUPHView All CompetitorsInsiders & InstitutionsCoppell Advisory Solutions LLCBought 1,732 shares on 8/17/2023Ownership: 0.003%Alliancebernstein L.P.Sold 34,952 shares on 8/15/2023Ownership: 0.361%HighVista Strategies LLCSold 11,930 shares on 8/15/2023Ownership: 0.068%Citadel Advisors LLCSold 1,400 shares on 8/15/2023Ownership: 0.000%Boothbay Fund Management LLCSold 26,561 shares on 8/15/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions MRUS Stock - Frequently Asked Questions Should I buy or sell Merus stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRUS shares. View MRUS analyst ratings or view top-rated stocks. What is Merus' stock price forecast for 2023? 10 equities research analysts have issued twelve-month price targets for Merus' stock. Their MRUS share price forecasts range from $35.00 to $49.00. On average, they predict the company's share price to reach $44.33 in the next twelve months. This suggests a possible upside of 78.7% from the stock's current price. View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts. How have MRUS shares performed in 2023? Merus' stock was trading at $15.47 at the beginning of the year. Since then, MRUS stock has increased by 60.4% and is now trading at $24.81. View the best growth stocks for 2023 here. When is Merus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our MRUS earnings forecast. How were Merus' earnings last quarter? Merus (NASDAQ:MRUS) issued its quarterly earnings data on Monday, August, 7th. The biotechnology company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.20. The biotechnology company earned $10.48 million during the quarter, compared to the consensus estimate of $10.38 million. Merus had a negative net margin of 432.68% and a negative trailing twelve-month return on equity of 69.89%. What ETFs hold Merus' stock? ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco NASDAQ Future Gen 200 ETF (QQQS). What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC). When did Merus IPO? (MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. What is Merus' stock symbol? Merus trades on the NASDAQ under the ticker symbol "MRUS." Who are Merus' major shareholders? Merus' stock is owned by many different retail and institutional investors. Top institutional investors include Commodore Capital LP (8.02%), VR Adviser LLC (3.46%), BVF Inc. IL (3.21%), Franklin Resources Inc. (3.19%), Braidwell LP (3.09%) and BlackRock Inc. (2.38%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Merus' stock price today? One share of MRUS stock can currently be purchased for approximately $24.81. How much money does Merus make? Merus (NASDAQ:MRUS) has a market capitalization of $1.24 billion and generates $41.59 million in revenue each year. The biotechnology company earns $-131,190,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis. How many employees does Merus have? The company employs 164 workers across the globe. How can I contact Merus? Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The official website for the company is www.merus.nl. The biotechnology company can be reached via phone at (130) 253-8800 or via email at enquiries@merus.nl. This page (NASDAQ:MRUS) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.